Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Graft Rejection: early-phase trial registry
3 of 6 indexed Graft Rejection trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #2,866 of 28,707 conditions by registered trial count.
6 US clinical trials · 3 currently recruiting · #2,866 of 28,707 conditions by registered trial count
Graft Rejection: 6 US clinical trials tracked, 3 recruiting.
Graft Rejection is the subject of 6 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Inova Health Care Services, running 2 of these trials.
Enrollment posture brief
Registry condition graft-rejection
OPEN 3 | RECR 50% | LATE 0 | EARLY 1 | RANK #2866 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Achalasia (50% recruiting · 8 trials)
Graft Rejection lists 3 open slots (50% of 6 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Graft Rejection on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Graft Rejection is recruiting above its size-band peers.
3 of 6 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Graft Rejection research.
Inova Health Care Services accounts for 2 of 6 trials (33.3%). 5 distinct sponsors appear on at least one study for this condition label.
-
Typical Graft Rejection enrolment sits around 250 participants.
Median target enrolment is 250 among the 6 trials that report a genuine target (sentinel values excluded). 1 of those (16.7%) plan for fewer than 100 participants.
-
Graft Rejection research leans observational.
2 interventional and 4 observational studies make up this index (33.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
6 total, page 1 of 1
Long-term Evaluation and Follow-up Care of Patients Treated With Stem Cell Transplants
National Heart, Lung, and Blood Institute (NHLBI)
NCT00106925
OPtimal Adult Heart Transplant Immunosuppression With MicroRNA Levels
Inova Health Care Services
NCT06939751
Optimal Pediatric Heart Transplant Immunosuppression With MicroRNAs
Inova Health Care Services
NCT06532890
Cardiac Allograft Rejection Gene Expression Observational (CARGO) II STUDY
XDx
NCT00761787
A Study to Evaluate the Effect of Thymoglobulin and Reduced Doses of Steroids to Prevent Renal Transplant Rejection
Genzyme, a Sanofi Company
NCT00089947
HLA-Identical Sibling Renal Transplant Tolerance
Northwestern University
NCT00619528
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Graft Rejection records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Graft Rejection trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Graft Rejection page
6 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Graft Rejection trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Inova Health Care Services sponsors the most Graft Rejection trials on record, review their full trial history before evaluating a specific study. See Inova Health Care Services's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Graft Rejection condition card totals 6 registered trials; most-linked intervention Thymoglobulin [Anti-Thymocyte Globulin (Rabbit)]; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.